Ashwin Kishtagari, Assistant Professor at Vanderbilt-Ingram Cancer Center, shared on X:
” Naveen Pemmaraju explores the potential of novel JAK inhibitors in myelofibrosis at the 2024 Summit on Hematological Cancers in Nashville: Are we on the brink of redefining treatment strategies and improving patient outcomes?”
